Introduction
Wiskott-Aldrich syndrome (WAS) was recognized as a unique clinical entity by Wiskott, who in 1936 delineated this syndrome from idiopathic thrombocytopenia or 'Morbus Werlhofii' by recognizing the association of thrombocytopenia, bloody diarrhea, eczema, and recurrent otitis media in three male infants (but not their sisters). Aldrich rediscovered this syndrome in 1954 and clearly established an X-linked recessive inheritance. Immunodeficiency, increased risk of autoimmunity and malignancies, and abnormalities of platelets were subsequently recognized [1] . Bone marrow (hematopoietic stem cell) transplantation, first reported in 1968 [2] , has been shown to be the only curative therapy [3] . In 1994, a multi-institutional survey reported detailed clinical and laboratory findings in 154 patients with classic WAS, confirming the high incidence of autoimmune diseases and often fatal outcome in WAS [4] .
In the same year the gene responsible for WAS/X-linked thrombocytopenia (XLT) was identified by positional cloning and designated as the WAS protein (WASP) gene [5] . The WASP gene was found to be mutated not only in classic WAS patients, but also in patients with XLT [6-8], which had been considered for many years to be an attenuated form of WAS because of its congenital thrombocytopenia, but without immunodeficiency or eczema [9] . Recent reports have expanded the WASP mutation phenotype to include intermittent XLT [10 . ], X-linked neutropenia with or without myelodysplasia [11, 12] or WAS/XLT in females with heterozygous mutations [13,14 . -16 . ].
WASP was considered a novel protein with unknown function until the discovery of neural WASP (N-WASP)
[17] and other members of the 'WASP family' of proteins including the WAVE/SCARs (WASP family, Verprolin homology domain containing protein/Suppressor of cAMP receptor) which have been found conserved in a wide variety of species (human, mouse, rat, bovine, Drosophila, yeasts). These proteins play an important role in the organization of actin in the cells [18 . . ,19] .
In this review we will focus on recent clinical and molecular findings that provide new insight into the pathogenesis of this complex disease and the correlation of genotype and phenotype.
WASP and WASP-binding molecules
WASP is a hematopoietic cell specific protein with several functional domains (Fig. 1) , by which WASP interacts with a number of cytoplasmic molecules (Table   1 ) involved in signal transduction and reorganization of the cytoskeleton by activating Arp2/3-mediated actin polymerization (reviewed in [18 . . ,20 . ]).
In its resting state, WASP forms an autoinhibitory loop through binding of the C-terminal region, which contains a globular actin monomer binding verprolin homology (VH) domain, a cofilin homology (CH) domain, and an acidic region (AR), to the hydrophobic core of the Cdc42/Rac GTPase-binding domain (GBD) [21] . The GTP bound activated form of Cdc42 disrupts this autoinhibitory loop and releases the proline rich region (PRR) and the C-terminal region to bind to profilin, globular actin monomer, and the Arp2/3 complex. The Arp2/3 complex, which is composed of seven polypeptides, nucleates actin polymerization which is accelerated by profilin and thus contributes to filamentous actin In the resting state (upper panel), Wiskott-Aldrich syndrome protein (WASP) forms an intramolecular autoinhibitory structure with binding of the verprolin homology/cofilin homology/acidic region (VCA) domain to the small G protein binding domain (GBD). WASP-interacting protein (WIP) binds constitutively with its proline-rich region (PRR) domain to the PH/WH1/EVH1 (pleckstrin homology/WASP homology 1/enabled-VASP homology 1) domain of WASP. WIP also interacts constitutively with CrkL. After activation, GTP bound Cdc42 dissociates itself from the autoinhibitory structure of WASP leading to actin polymerization via Arp2/3 complex. Tyrosine kinases phosphorylate the tyrosine 291 (Y 291 ) residue, and CK2 phosphorylates the serine 483 and 484 residues (SS 483, 484 ) that enhance the actin polymerization activity of WASP. BR, basic region.
formation (reviewed in [22 . . ]). WASP binding molecules, phosphatidylinositol-4,5-biphosphate (PI(4,5)P 2 ) and Nck (Table 1) Phosphorylation of WASP was shown to enhance the actin polymerization activity of WASP. Hck, a hematopoietic cell specific Src-type tyrosine kinase, has been found to be the latest partner of WASP. Hck binds and phosphorylates WASP on tyrosine 291 as does Btk [45] , a process that enhances the actin polymerization activity of WASP via the Arp2/3 complex [31 . ,46 . ]. Similarly, phosphorylation of serine 483 and 484 in the cofilin homology domain of WASP by casein kinase 2 increases the affinity of the C-terminal region for the Arp2/3 complex and is required for efficient actin polymerization in vitro [47 . ]. N-terminal domains of WASP and N-WASP were originally reported by sequence alignment to be a pleckstrin homology (PH) domain and to bind to PI(4,5)P 2 using an ELISA method and PI(4,5)P 2 specific antibody [17, 43] . Subsequent structural analysis revealed that this domain is a distinct member of the PH domain superfamily called WH1/EVH1 (WASP-homology 1/ enabled-VASP homology 1) domain which binds to proline rich peptides [48] [49] [50] but not to PI(4,5)P 2 when using lipid vesicle binding assays and ultracentrifugation [44 . ]. Volkman and co-workers [44 . ] showed that PI(4,5)P 2 binds to basic region and GBD-derived peptides.
WASP-interacting protein (WIP) was found to be a binding partner of WASP by the yeast two hybrid method and by immunoprecipitation from lymphocytes [32] . It is ubiquitously expressed and is reported to participate in fillopodium formation [51] , ruffle formation [52] and vesicle movement [53] . WIP has a proline rich region in its C-terminal region which constitutively binds to the PH/WH1/EVH1 domain [44 . ]. Most missense This is in spite of the fact that WIP is widely expressed and binds to both WASP and N-WASP [32,44 . ]. Whereas WIP seems dispensable for T-and B-lymphocyte development, WIP is essential for T-cell activation via the T-cell receptor (TCR)/CD3 complex: WIPdeficient T cells show impaired proliferation and IL-2 secretion in response to anti-CD3 stimulation. Addition of IL-2 to the culture system rescued the proliferation in response to anti-CD3 stimulation. WIP-deficient T cells fail to increase the filamentous actin content or to form protrusions and pseudopodia following TCR/CD3 ligation. Alternatively, responses to PMA + ionomycin were normal [55 . . ]. The abnormalities observed in WIPdeficient T cells are similar, but more profound than those seen in WASP-deficient mice [56, 57] . These observations suggest a critical role for WIP in T-cell activation via TCR/CD3, and the WASP-deficient T-cell defect reported may be partially due to defective signaling via WIP. Interestingly, B cells of WIP-deficient mice showed increased proliferation and IL-2 receptor expression in response to various stimulations, suggesting a negative regulatory effect of WIP. Antibody responses to a T-independent antigen were normal, but were impaired to a T-dependent antigen [55 . . ] .
T-lymphocyte and NK cell abnormalities in WAS patients
Reorganization of the actin cytoskeleton is required for the establishment of immunological synapses between T lymphocytes and antigen-presenting cells, as well as between cytotoxic T lymphocytes or NK cells and their targets. On the T-cell side, the immunological synapse comprises a central area containing the TCR complex, and CD2 and CD28 molecules, and a peripheral rim in which adhesion molecules are accumulated. These local modifications are associated with a focal process of actin polymerization. Although the immunological synapse is not involved in the initiation of TCR-mediated signaling, it ensures optimal T-cell activation and localized effector activity. Following TCR ligation, WASP, WIP, CrkL and ZAP-70 are rapidly recruited to lipid rafts that are membrane platforms which allow lateral movements of the TCR complex and associated kinases. WASP is also required for the immunological synapse formation WASP may also be involved in T-lymphocyte trafficking, as indicated by the fact that stromal-derived factor-1a (SDF-1a)/CXCL12, a well-studied T-cell chemoattractant, induces tyrosine phosphorylation of WASP and of some adaptors (Nck, Cas) that are involved in cell migration [64] .
The minimal region of WASP required to direct cellular movement is the C-terminal VCA (VH/CH/AR) region, which is also the minimal region required for stimulating actin nucleation [65 . ]. Phagocytic defects are also seen in WASP-deficient macrophages and neutrophils [66] . Lentiviral-mediated transfection of WASP into WAS macrophages restores these abnormalities and normalizes chemotaxis in response to colony stimulating factor-1 (CSF-1) [67 . ].
Gene therapy for human WASP-deficient cells and WASP-deficient mice
Although bone marrow transplantation from an HLAmatched donor (sibling or unrelated) has an excellent rate of success, especially if performed during the first 5 years of life (5-year probability of survival 87%) [3], many patients do not have a suitable donor. One source of hematopoietic stem cells is unrelated, partially HLAmatched cord blood and has been performed successfully [68 . ,69].
Another treatment approach, gene therapy, is being actively investigated. Retrovirus-mediated WASP gene transfer into B-cell lines corrected the cell surface abnormality of glycoproteins and the defective actin polymerization [70, 71] . Human WASP-deficient T cells (primary cells [72 . ] and HTLV-1 (human T lymphotrophic virus-1) transformed T-cell lines [73 . ]) transduced with retroviral vectors encoding WASP expressed WASP that was able to bind to SH3 containing proteins (Grb2, phospholipase C (PLC)-g1, and Fyn) and to proliferate and polymerize actin in response to anti-CD3 stimulation. No toxic effect as a result of overexpression of WASP was observed with retrovirus-mediated gene transfer.
To test the feasibility and safety of gene therapy, Waspdeficient mice who in concordance with WAS patients have impaired T-cell receptor-induced proliferation and aberrant cytoskeleton rearrangement [56, 57] , underwent gene therapy [74 . ]. Hematopoietic stem cells obtained from WASP-deficient mice were transduced with WASPexpressing retroviruses and transferred into RAG2deficient mice after total body irradiation (WASPdeficient mice developed severe colitis after total body irradiation and did not survive the procedure). Mature B and T lymphocytes developed in normal numbers and TCR induced proliferation was significantly improved in the RAG2-deficient mice after transplantation of Wasp gene transduced hematopoietic stem cells. Competitive repopulation experiments by transplanting a mixture of wild type and WASP-deficient bone marrow cells revealed a selective advantage of wild type cells in spleen but not in bone marrow or thymus [74 . ]. Although transient ectopic overexpression of WASP has been reported to be associated with dramatic changes in the actin cytoskeleton [36] , retrovirus-mediated WASP expression does not seem to have such a toxic effect [70,71,72 . ,74 . ].
The observation of spontaneous in-vivo reversion of WASP mutations also suggests a growth advantage of T cells with expression of a normal WASP gene [75, 76] .
WAS gene mutations and phenotype
A correlation between clinical phenotype and genotype was reported independently by several investigators [77] [78] [79] but not observed by others [80, 81] .
Over 400 patients with WASP gene mutation have been reported to date. The mutations, WASP expressions and the phenotypes reported are accessible on the Internet as WASPbase [82 . ]. Using a simple scoring system [78,83 . ], the severity of the clinical phenotype can be assessed (Table 3) . All but four patients with WASP mutations (two intermittent XLT, two X-linked neutropenia, see below) have chronic thrombocytopenia which is a common finding of WAS (with immunodeficiency, score 3, 4) and XLT (without immunodeficiency, score 1, 2). Forty-six percent of all WASP gene mutated patients have null mutations (nonsense mutations, deletions, insertions with frameshift), 42% have missense mutations and 12% have splice anomalies (Table  4 ). The majority of the missense mutations are located in the PH/WH1/EVH1 domain ( Table 5 ). The most frequently reported missense mutation affects Arg86 (36 patients) ( Table 2) . Data provided in published reports fail to demonstrate a clear correlation of genotype/protein expression and phenotype, since 42% (14/33) of patients with Arg86Cys or Arg86His mutation are WASP positive and have a WAS phenotype. Such a discrepancy was also reported by Schindelhauer et al. [81] . Interestingly, Arg86 is an important site for the interaction of WASP and WIP [44 . ,84]. By contrast, two large referral centers, using the scoring system described above, observed that of 19 patients from 17 unrelated families with missense mutations affecting Arg86, one patient had a score of 3 (WAS phenotype), two had scores of 2-3 and the remaining 16 patients had XLT with scores of 1 (3) and 2 (13). All patients but two had demonstrable WASP by Western blot, although the amount was consistently reduced (L. Notarangelo and H.D. Ochs, unpublished observation). The exclusion of patients with mutations of Arg86 listed in Table 2 improves the correlation of genotype-WASP expression and phenotype: 83.3% of patients with missense mutations other than Arg86 who are also WASP positive have the XLT phenotype. WAS, Wiskott-Aldrich syndrome; XLT, X-linked thrombocytopenia; XLN, X-linked neutropenia. A recent analysis evaluated the clinical phenotype, the genotype and WASP expression in a large cohort of Japanese WASP gene mutated patients. Susceptibility to infections, severe eczema, intestinal hemorrhage, death due to intracranial bleeding and malignancy were highly associated with lack of WASP expression by patient lymphoctyes. Overall survival and survival without intracranial hemorrhage were significantly lower in WASP negative patients. This observation strongly suggests that the long-term clinical outcomes correlated with WASP expression [69] . ].
In the study from Japan [69] , 22% of patients with classic WAS (6/27) presented with autoimmune disease and two of those six patients also developed malignancies. The relatively low incidence of autoimmune disease in the Japanese patients can be explained by the younger age of the patients and the higher percentage (52%) of patients receiving stem cell transplantation at an early age (mean age 2.3 years). Although several cases of autoimmune diseases in XLT have been reported, the incidence of this complication in XLT is unknown. Of the 23 Japanese patients with the XLT phenotype, six (26%) reported autoimmune or inflammatory disease, including five boys who had developed IgA nephropathy [69] .
Two unexpected clinical phenotypes due to missense mutations of the WASP gene have recently been recognized.
Two Italian families in which affected males presented with intermittent thrombocytopenia were found to have missense mutations in exon 2 (P58R) and exon 11 (I481N), respectively [10 . ]. Affected patients experienced normal platelet numbers at times, followed by periods of thrombocytopenia. They did not have splenectomy and were originally considered to have recurrent idiopathic thrombocytopenia. The reduced platelet volume, which is not consistent with idiopathic thrombocytopenia, led to WASP gene analysis and the discovery of two novel missense mutations affecting the PH/WH1/EVH1 and the CH domains. A normal amount of WASP protein was observed in B-cell lines and platelets from affected males.
Two families with X-linked neutropenia and a maturation arrest at the promyelocyte/myelocyte stage without microthrombocytopenia or eczema were found to have missense mutations within the GBD domain (L270P and I294T, respectively) [ 
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